Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Orthogen AG
DescriptionAutologous injection of interleukin-1 (IL-1) receptor antagonist protein
Molecular Target Interleukin-1 (IL-1) receptor antagonist (IL-1RA)
Mechanism of ActionInterleukin-1 (IL-1) receptor antagonist
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase III
Standard IndicationPain
Indication DetailsTreat chronic knee pain due to osteoarthritis (OA)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today